Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 7, 2013, Pages 728-735

  Vanfleteren, Lowie E G W ^a,b,g   Spruit, Martijn A ^a   Groenen, Miriam ^a   Gaffron, Swetlana ^c   Van Empel, Vanessa P M ^a,d   Bruijnzeel, Piet L B ^e   Rutten, Erica P A ^a   Roodt, Jos Op't ^f   Wouters, Emiel F M ^a,b   Franssen, Frits M E ^a,b  

^a Centre of Expertise for Chronic Organ Failure   (Netherlands)

^b Department of Respiratory Medicine ^*  (Netherlands)

^c Viscovery Software GmbH   (Austria)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e ASTRAZENECA R AND D   (Sweden)

^f MAASTRICHT UNIVERSITY   (Netherlands)

^g CIRO Center of Expertise for Chronic Organ Failure   (Netherlands)

Author keywords

Chronic obstructive pulmonary disease; Cluster analysis; Comorbidity; Systemic inflammation

Indexed keywords

INTERLEUKIN 6; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CACHEXIA; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE SEVERITY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AGED; BIOLOGICAL MARKERS; CACHEXIA; CARDIOVASCULAR DISEASES; CLUSTER ANALYSIS; COMORBIDITY; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MENTAL DISORDERS; METABOLIC DISEASES; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGRESSION ANALYSIS; TUMOR NECROSIS FACTORS;

EID: 84875847989     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201209-1665OC     Document Type: Article

References (47)

1. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, MacNee W, Miller BE, Rennard S, Silverman EK, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010;11:122.
2. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-365.
3. von Leupoldt A, Taube K, Lehmann K, Fritzsche A, Magnussen H. The impact of anxiety and depression on outcomes of pulmonary rehabilitation in patients with COPD. Chest 2011;140:730-736.
4. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008;32:962-969.
5. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, Zulueta J, Cabrera C, Zagaceta J, Hunninghake G, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:155-161.
6. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA. Ascertainment of cause-specific mortality in COPD: operations of the TORCH clinical endpoint committee. Thorax 2007;62:411-415.
7. Antonelli Incalzi R, Fuso L, De Rosa M, Forastiere F, Rapiti E, Nardecchia B, Pistelli R. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997;10:2794-2800.
8. Crisafulli E, Costi S, Luppi F, Cirelli G, Cilione C, Coletti O, Fabbri LM, Clini EM. Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax 2008;63:487-492.
9. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010;65:956-962.
10. Schnell KM, Weiss CO, Lee T, Krishnan JA, Leff B, Wolff JL, Boyd C. The prevalence of clinically-relevant comorbid conditions in patients with COPD: a cross-sectional study using data from NHANES 1999-2008. BMC Pulm Med 2012;12:26.
11. Siebeling L, Puhan MA, Muggensturm P, Zoller M, Ter Riet G. Characteristics of Dutch and Swiss primary care COPD patients: baseline data of the ice cold ERIC study. Clin Epidemiol 2011;3:273-283.
12. van Manen JG, Bindels PJ, Ijzermans CJ, van der Zee JS, Bottema BJ, Schade E. Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol 2001;54: 287-293.
13. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005;128:2099-2107.
14. Vanfleteren LE, Franssen FM, Uszko-Lencer NH, Spruit MA, Celis M, Gorgels AP, Wouters EF. Frequency and relevance of ischemic electrocardiographic findings in patients with chronic obstructive pulmonary disease. Am J Cardiol 2011;108:1669-1674.
15. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012; 380:37-43.
16. Sabit R, Bolton CE, Edwards PH, Pettit RJ, Evans WD, McEniery CM, Wilkinson IB, Cockcroft JR, Shale DJ. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:1259-1265.
17. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33:1165-1185.
18. Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:982-988.
19. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, Vestbo J, Lomas DA, Calverley PM, Wouters E, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE 2012;7:e37483.
20. Vanfleteren LE, Spruit MA, Franssen FM, Groenen M, Wouters EFM. Objectified co-morbidities in patients with COPD: the CIROCO study. Am J Respir Crit Care Med 2012;185:A3674.
21. Spruit MA, Vanderhoven-Augustin I, Janssen PP, Wouters EF. Integration of pulmonary rehabilitation in COPD. Lancet 2008;371:12-13.
22. Tooth L, Hockey R, Byles J, Dobson A. Weighted multimorbidity indexes predicted mortality, health service use, and health-related quality of life in older women. J Clin Epidemiol 2008;61:151-159.
23. Burgel PR, Paillasseur JL, Caillaud D, Tillie-Leblond I, Chanez P, Escamilla R, Court-Fortune I, Perez T, Carre P, Roche N. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 2010;36:531-539.
24. Garcia-Aymerich J, Gomez FP, Benet M, Farrero E, Basagana X, Gayete A, Pare C, Freixa X, Ferrer J, Ferrer A, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax 2011;66:430-437.
25. Burgel PR, Paillasseur JL, Peene B, Dusser D, Roche N, Coolen J, Troosters T, Decramer M, Janssens W. Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality. PLoS ONE 2012;7:e51048.
26. Burgel PR, Roche N, Paillasseur JL, Tillie-Leblond I, Chanez P, Escamilla R, Court-Fortune I, Perez T, Carre P, Caillaud D. Clinical COPD phenotypes identified by cluster analysis: validation with mortality. Eur Respir J 2012;40:495-496.
27. Chandra D, Stamm JA, Palevsky PM, Leader JK, Fuhrman CR, Zhang Y, Bon J, Duncan SR, Branch RA, Weissfeld J, et al. The relationship between pulmonary emphysema and kidney function in smokers. Chest 2012; 142:655-662.
28. Bon J, Fuhrman CR, Weissfeld JL, Duncan SR, Branch RA, Chang CC, Zhang Y, Leader JK, Gur D, Greenspan SL, et al. Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. Am J Respir Crit Care Med 2011;183:885-890.
29. Bolton CE, Ionescu AA, Shiels KM, Pettit RJ, Edwards PH, Stone MD, Nixon LS, Evans WD, Griffiths TL, Shale DJ. Associated loss of fatfree mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:1286-1293.
30. Filley GF, Beckwitt HJ, Reeves JT, Mitchell RS. Chronic obstructive bronchopulmonary disease: II. Oxygen transport in two clinical types. Am J Med 1968;44:26-38.
31. Kirchberger I, Meisinger C, Heier M, Zimmermann AK, Thorand B, Autenrieth CS, Peters A, Ladwig KH, Doring A. Patterns of multimorbidity in the aged population: results from the KORA-age study. PLoS ONE 2012;7:e30556.
32. Hanssen TA, Nordrehaug JE, Eide GE, Bjelland I, Rokne B. Anxiety and depression after acute myocardial infarction: an 18-month followup study with repeated measures and comparison with a reference population. Eur J Cardiovasc Prev Rehabil 2009;16:651-659.
33. Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis factoralpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994;150:1453-1455.
34. Iwamoto H, Yokoyama A, Kitahara Y, Ishikawa N, Haruta Y, Yamane K, Hattori N, Hara H, Kohno N. Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med 2009;179:35-40.
35. Watz H, Waschki B, Kirsten A, Muller KC, Kretschmar G, Meyer T, Holz O, Magnussen H. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 2009;136:1039-1046.
36. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-1519.
37. Broekhuizen R, Grimble RF, Howell WM, Shale DJ, Creutzberg EC, Wouters EF, Schols AM. Pulmonary cachexia, systemic inflammatory profile, and the interleukin 1beta -511 single nucleotide polymorphism. Am J Clin Nutr 2005;82:1059-1064.
38. Graat-Verboom L, Spruit MA, van den Borne BE, Smeenk FW, Martens EJ, Lunde R, Wouters EF. Correlates of osteoporosis in chronic obstructive pulmonary disease: an underestimated systemic component. Respir Med 2009;103:1143-1151.
39. Mills NL, Miller JJ, Anand A, Robinson SD, Frazer GA, Anderson D, Breen L, Wilkinson IB, McEniery CM, Donaldson K, et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax 2008;63: 306-311.
40. Quint JK, Baghai-Ravary R, Donaldson GC, Wedzicha JA. Relationship between depression and exacerbations in COPD. Eur Respir J 2008; 32:53-60.
41. Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav 2008;94: 206-218.
42. Poulain M, Doucet M, Drapeau V, Fournier G, Tremblay A, Poirier P, Maltais F. Metabolic and inflammatory profile in obese patients with chronic obstructive pulmonary disease. Chron Respir Dis 2008;5:35-41.
43. Breyer MK, Spruit MA, Celis AP, Rutten EP, Janssen PP, Wouters EF. Highly elevated c-reactive protein levels in obese patients with COPD: a fat chance? Clin Nutr 2009;28:642-647.
44. Rutten EP, Breyer MK, Spruit MA, Hofstra T, van Melick PP, Schols AM, Wouters EF. Abdominal fat mass contributes to the systemic inflammation in chronic obstructive pulmonary disease. Clin Nutr 2010;29:756-760.
45. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 2000;51:245-270.
46. Incalzi RA, Corsonello A, Pedone C, Battaglia S, Paglino G, Bellia V. Chronic renal failure: a neglected comorbidity of COPD. Chest 2010; 137:831-837.
47. Almagro P, Cabrera FJ, Diez J, Boixeda R, Ortiz B, Murio C, Soriano JB. Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the Epoc en Servicios de Medicina Interna (ESMI) study. Chest 2012;142:1126-1133.